MDGL Q3 2019 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$28,000

Operating Income

-$24M

Net Income

-$21M

EPS (Diluted)

$-1.39

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$456M

Total Liabilities

$16M

Stockholders' Equity

$440M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$28,000	-$24,000	-16.7%
Operating Income	-$24M	-$11M	-113.5%
Net Income	-$21M	-$9M	-151.8%